Transforming Healthcare Through Strategic AI Integration: A Partnership Approach to Medical Device and Life Sciences Innovation

Articles

Feb 23

Co-Authored by Springboard Solutions LLC in partnership with Valere

The healthcare industry stands at a critical inflection point. Medical device manufacturers and life sciences organizations face mounting pressure from evolving regulatory frameworks, accelerating technological change, and rising quality expectations. Between 2020 and 2024 alone, the industry navigated over 15 landmark regulations, 60+ major guidelines, and 100 technical amendments.¹ Artificial intelligence has emerged as a genuinely transformative force in this environment, but it has also introduced a new layer of complexity that most organizations are not yet equipped to manage.

And yet, for all the investment and enthusiasm, AI’s promise in healthcare remains largely unrealized. 87% of AI initiatives stall between pilot and production, and 95% never generate measurable ROI. In our experience, the root cause is almost never the technology itself. It is a structural problem. When strategy, development, workforce readiness, and deployment are handled by separate vendors, the client ends up as the de facto systems integrator, with no single party truly accountable for whether it works. The result is a lot of impressive presentations and very little operational change.

What actually works is a different model entirely: one that combines deep systems integration expertise with end-to-end AI value delivery, implemented in a way that is modular, scalable, and financially practical. That is the foundation of the partnership between Springboard Solutions LLC and Valere, and it is what this article is about.

The Partnership: Integration Expertise Meets AI Value Delivery

The Springboard Solutions–Valere partnership brings together two complementary capabilities that are rarely found in a single engagement:

Springboard Solutions Valere

39 years of engineering, Award-winning AI value creation partner

operations & regulatory leadership (Clutch Top AI Company 2024)

Process and systems mapping 300+ digital products delivered

before any AI solution is proposed across healthcare, fintech, logistics

Regulatory compliance embedded Valere Evolve platform:

from day one Learning → Labs → Conducto/Dactic

FDA 21 CFR 820 / ISO 13485 expertise End-to-end accountability from strategy

across the full device lifecycle through production deployment

Bidirectional traceability across RM, 220+ in-house technical experts

CAD, QMS, PLM, MES, ERP across five global offices

Springboard Solutions: Built on Integration Experience

Springboard Solutions LLC brings 39 years of progressive high-technology experience across defense, telecommunications, semiconductor manufacturing, and medical devices. That cross-industry background matters because the integration challenges in those fields are genuinely complex, and the lessons transfer directly to healthcare.

The clearest example is Springboard Solutions founder’s work on proton radiation therapy systems, one of the most technically demanding integration projects in the medical device industry. The systems spanned particle accelerators, 100-ton precision mechanical positioning, robotics, x-ray imaging, treatment planning software, patient monitoring, and facility integration—all developed under FDA 21 CFR 820 and ISO 13485 simultaneously.

Founder Dan Raymond held a rare dual role throughout that project, serving as both VP of Engineering and Acting Director of Quality and Regulatory. That combination of perspectives—managing the technical build while owning the compliance posture—shaped a practical understanding of what it actually takes to integrate people, processes, tools, and technology in a regulated environment. Specific experience includes:

• Architecting integrated Requirements Management, CAD, QMS, PLM, MES, and ERP systems with bidirectional traceability

• Member of executive 510(k) clearance submission team for one of the industry’s most complex devices which obtained FDA approval

• Navigating FDA inspections and managing remediation of 483 observations

• Building modular system architectures that scale without requiring complete rebuilds

• Designing integration frameworks that eliminate redundant data entry and reduce compliance overhead

Valere: AI Value Delivery From Strategy Through Deployment

Valere is an award-winning AI value creation and delivery partner, recognized by Clutch as a Top AI Company in 2024. The firm has delivered over 300 digital products across healthcare, fintech, sports technology, logistics, and more. What distinguishes Valere in practice is not just the breadth of the portfolio but the ownership model behind it.

One thing Valere has learned repeatedly in healthcare AI engagements is that the most dangerous moment in any AI project is the handoff. Strategy to development. Development to deployment. Deployment to the team that actually has to use it. Every one of those transitions is an opportunity for accountability to disappear. Valere’s model is built specifically to eliminate those gaps through a single centralized platform—Valere Evolve—which integrates the full delivery ecosystem:

Platform Component What It Does Why It Matters

Valere Learning AI literacy, upskilling, A well-built system that a team does

and workforce education not understand or trust will not deliver value

Valere Labs Custom software development 220+ in-house technical experts

and managed services across five global offices

Conducto & Dactic End-to-end AI orchestration, The infrastructure that moves AI from working

scaling, knowledge capture, prototype to production system generating

and data enrichment real results

Why This Partnership Works

The combination is straightforward in principle but difficult to replicate in practice. Springboard evaluates and maps the operational and regulatory landscape before any AI solution is proposed. That foundation work—understanding how data flows, where systems break down, and what the compliance requirements actually demand—is what allows Valere to deploy AI against real, identified problems rather than hypothetical ones.

In practice, this means:

• Process and systems mapping happens before any AI discussion begins

• AI is proposed only where specific gaps have been documented

• Valere owns the full delivery lifecycle so accountability never fragments

• Compliance requirements are embedded in the architecture from day one, not addressed after deployment

• Investments are modular and staged so organizations are not committing to a full transformation before they have seen early results

A Phased Approach: Starting Where You Are

Successful AI integration in healthcare does not begin with the most sophisticated use case. It begins with the most tractable one. The FDA’s own experience with internal AI tools illustrates why: early implementations that reduced documentation review time from days to minutes also revealed errors that required careful correction, reinforcing that deliberate, human-verified deployment is not optional in this environment.²

Valere has consistently found that organizations get the most durable results when they start with high-volume, lower-risk workflows where the feedback loop is fast and the ROI is visible early. That early success builds the internal trust and organizational readiness needed to expand into more complex applications. The Valere Evolve platform is designed to support each phase—with workforce enablement through Valere Learning, technical development through Valere Labs, and production scaling through Conducto and Dactic—so the infrastructure that supports phase one is the same infrastructure that scales into phase three.

What This Looks Like in Practice: Documented Outcomes in Healthcare and Life Sciences

The four engagements below are not illustrative examples of what this approach could produce. They are documented outcomes from healthcare and life sciences organizations that faced exactly the challenges this partnership addresses:

Organization Challenge Solution Outcome

Unno Healthcare Patient data fragmented Unified AI-driven platform Improved care transparency,

(Omnia Health) across disconnected systems; consolidating all patient operational efficiency,

PCPs lacked visibility data with smart and physician engagement

for confident clinical notifications and

decisions integrated data flows

Johns Hopkins Alzheimer’s research data Unified research platform Improved data accuracy;

(Lucidity) generated across caregivers, integrating mobile, web, enabled predictive insights

patients, and researchers IoT, and ML to mine cognitive previously impossible;

could not be connected function and daily variables supported $200K+ in

for comprehensive analysis research funding

Fullscript Enormous supplement and Retrieval-Augmented Fundamentally changed how

treatment data repository Generation (RAG) AI platform practitioners access data;

with no practical way to tailored to Fullscript’s data improved personalized care

surface the right environment and delivery and patient

information at point of care practitioner workflows treatment adherence

Wellth AI communicating directly Secure Human-in-the-Loop Every AI-generated message

with patients without structured portal with real-time compliant, auditable, and safe

oversight—every automated validation, performance before reaching a

message a potential compliance metrics, and immutable patient—compliance as

failure trails architecture, not

(Salesforce + AWS Bedrock) afterthought

Application: Medical Device Business Systems Integration

Medical device manufacturers commonly operate with requirements management, CAD, QMS, PLM, MES, and ERP systems that function as isolated platforms with minimal meaningful integration. The practical result is manual data entry, traceability gaps, and escalating compliance risk, particularly as the FDA’s QMSR demands comprehensive bidirectional traceability. The Unno Healthcare engagement is a useful reference point: siloed systems do not just create IT complexity, they degrade the quality of decisions made by the people who depend on them.

Springboard’s approach begins with understanding the business before recommending anything. That means evaluating what systems are in place, whether they are capable of supporting compliant processes, and mapping the complete operational landscape including design, manufacturing, verification and validation, and post-market surveillance. This assessment surfaces the gaps that actually matter: disconnects between systems, compliance vulnerabilities, and inefficiencies that add cost without adding value.

From that documented foundation, Valere identifies where AI can address specific, verified problems and takes ownership of delivery through the full lifecycle, from development through production deployment on the Valere Evolve platform. Drawing from the Wellth experience, compliance infrastructure including audit trails, validation workflows, and appropriate human oversight is embedded in the architecture rather than addressed as a separate workstream. Springboard maintains regulatory alignment throughout.

Organizations that take this approach typically see meaningful reductions in manual effort, lower quality and compliance costs, faster regulatory submissions, and positive ROI within 12 to 24 months, with an architecture that protects existing investments and scales incrementally.

Application: Life Sciences Data Mining for Early Disease Detection

Life sciences organizations working at the frontier of disease detection are sitting on enormous amounts of data that they cannot fully use. Historical patient records, clinical observations, laboratory results, imaging studies, genomic data, published research, and real-world evidence sources are often fragmented, inconsistently formatted, and siloed in ways that prevent comprehensive analysis. The Johns Hopkins engagement demonstrated directly what changes when that fragmentation is resolved: patterns that were previously undetectable become visible, and research programs that were limited by analytical constraints begin to generate new insight.

Springboard maps the current data landscape in detail before any solution is proposed: what is being collected, where it lives, how it moves between systems, and how it is currently being analyzed. That assessment consistently surfaces the same categories of gap: valuable data locked in incompatible systems, external sources that are not being accessed, manual processes that cannot scale, and integration disconnects that prevent researchers from seeing the full picture. The Fullscript engagement adds another dimension here: in life sciences as in digital health, organizations often have more analytical potential in their existing data than they realize, and the opportunity is frequently about access and integration rather than new data collection.

With those gaps documented, Valere takes ownership of the AI value delivery, deploying custom software development, Conducto and Dactic for knowledge capture and production scaling, and Valere Learning to build the internal capability to sustain and expand the system. Springboard ensures regulatory and documentation readiness throughout.

Organizations that take this approach achieve more comprehensive analytical coverage, improved ability to detect disease patterns earlier, and a scalable infrastructure for ongoing data integration, with appropriate governance and privacy protections built in.

Moving Forward

Most organizations that invest in healthcare AI do not fail because they chose the wrong technology. They fail because no single partner owned the outcome from beginning to end. The four engagements described here follow a consistent pattern: a clearly defined problem, integrated end-to-end delivery, and measurable results. That is the model this partnership is built on.

Springboard Solutions brings the regulatory integration framework and systems mapping expertise. Valere brings the platform and the end-to-end accountability for AI value delivery. Together, the approach is the same in every engagement: understand the current state thoroughly before proposing anything, build AI against documented gaps rather than hypothetical opportunities, and ensure that compliance is a structural feature of the system rather than a project phase.

Taking the First Step

Whether you are a medical device manufacturer navigating FDA’s new QMSR and struggling with fragmented business systems, a life sciences organization with data you cannot fully access or analyze, or a healthcare organization that has seen too many AI pilots go nowhere, the path forward is the same. Start with an honest assessment of where you are. Build from there with a partner who owns the outcome.

What We Offer Description

Readiness Complimentary systems integration and AI readiness assessments tailored to

Assessments medical device and life sciences organizations

Business Systems Comprehensive evaluation and process mapping to identify integration and data

Evaluation gaps across all business systems

Proof-of-Concept Demonstrate ROI for specific, identified opportunities before major commitments

Engagements are made

Implementation Roadmaps aligned with your regulatory timeline and business objectives

Roadmaps

Ongoing From foundational systems integration through deployed, production AI systems

Partnership

The future of healthcare innovation is AI implemented thoughtfully, integrated with proven systems, validated rigorously, scaled cost-effectively, and built with a single partner accountable for the outcome. Let’s build that together.